All In Biotech

Drug Trial Radar · NCT04741984

Monocyte Antigen Carrier Cells for Newly Diagnosed GBM

The DEMAND Study: Dose Escalation Study of Monocyte Antigen Carrier Cells for Newly Diagnosed Glioblastoma With Unmethylated MGMT Gene Promoter

Last checked: Nov 19, 2026Latest source record: May 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Aug 2023

Primary completion

May 2025

Study completion Nov 2025

Sponsor

Lead sponsor
Michael GunnAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Feb 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine the maximum tolerated dose (MTD) of MT-201-GBM (pp65CMV antigen monocytes) that will be administered to patients newly diagnosed with a type of brain tumor called glioblastoma (GBM) that has an unmethylated MGMT (O\[6\]-methylguanine-DNA methyltransferase) (MGMT) gene promoter.

Conditions

  • Glioblastoma
  • Glioma, Malignant

Interventions

  • MT-201-GBM monocyte vaccineBiological

    monocytes isolated from patient's leukapheresis loaded with CMV pp65-LAMP (Lysosomal-associated Membrane Protein) mRNA (Messenger Ribonucleic Acid)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of MT-201-GBMTime frame: 1 month after first infusion
  2. pp65 T-cell Immune Response After 2 Weeks Post Infusion Three Compared to BaselineTime frame: 2 weeks after third infusion

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.